Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sun Dec 18 08:27:29 UTC 2022
by
admin
on
Sun Dec 18 08:27:29 UTC 2022
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
NQI5D806LC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P28223
Created by
admin on Sun Dec 18 08:27:39 UTC 2022 , Edited by admin on Sun Dec 18 08:27:39 UTC 2022
|
PRIMARY | |||
|
NQI5D806LC
Created by
admin on Sun Dec 18 08:27:39 UTC 2022 , Edited by admin on Sun Dec 18 08:27:39 UTC 2022
|
PRIMARY | |||
|
P28223
Created by
admin on Sun Dec 18 08:27:39 UTC 2022 , Edited by admin on Sun Dec 18 08:27:39 UTC 2022
|
PRIMARY |
From | To |
---|---|
1_148 | 1_227 |
1_349 | 1_353 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_8 |
N | 1_38 |
N | 1_44 |
N | 1_51 |
N | 1_54 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
WEAK AGONIST->TARGET |
IC50
|
||
|
AGONIST -> TARGET |
Moderate selectivity over related serotonin receptors. It has lower 5-HT2 affinity and efficacy than the related compound AL-37350A, but higher lipophilicity.
Ki
|
||
|
INVERSE AGONIST->TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
LIGAND->TARGET |
|
||
|
INHIBITOR -> TARGET |
INHIBITOR
Ki
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
MAJOR
Ki
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
RADIOLIGAND->TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Ki
|
||
|
RADIOLIGAND->TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
Designed specifically as a peripherally selective drug, which does not cross the blood–brain barrier. AL-34662 has been shown to be potent and effective in the treatment of symptoms of glaucoma, with minimal side effects.
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
all of the tryptamines, including DMT but with the exception of psilocin, were more potent agonists at the 5-HT2A receptor than LSD in the assay that was used in the present study. LSD and psilocin were 5-HT2A receptor partial agonists, with 28% and 16% activation efficacy, respectively, whereas all of the other compounds presented higher 5-HT2A receptor activation efficacies (up to >80% for DiPT and 5-MeO-MiPT).
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
ANTAGONIST->TARGET | |||
|
AGONIST -> TARGET |
|
||
|
PARTIAL AGONIST->TARGET | |||
|
INHIBITOR -> TARGET | |||
|
RADIOLIGAND->TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Emax=94%
|
||
|
RADIOLIGAND->TARGET |
|
||
|
PARTIAL AGONIST->TARGET | |||
|
INHIBITOR -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
RADIOLIGAND->TARGET | |||
|
AGONIST->OFF-TARGET |
Ki
|
||
|
PARTIAL AGONIST->TARGET | |||
|
PARTIAL AGONIST->TARGET |
Emax=23%
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET |
PRECLINICAL
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
PARTIAL AGONIST->TARGET | |||
|
INVERSE AGONIST->TARGET |
AGONIST
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
WEAK INHIBITOR->TARGET |
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
PARTIAL AGONIST->TARGET |
Emax=25%
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
PARTIAL AGONIST->TARGET |
Emax=11%
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
INHIBITOR
Ki
|
||
|
AGONIST -> TARGET |
Could be an active psychedelic in humans, although it is not known to have been tested in humans and could be dangerous due to its strong inhibition of MAO-A.
|
||
|
INHIBITOR -> TARGET | |||
|
RADIOLIGAND->TARGET |
Ki
|
||
|
RADIOLIGAND->TARGET |
Ki
|
||
|
INVERSE AGONIST->TARGET |
Was under development for the treatment of insomnia. Development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints.recently, nelotanserin has been repurposed for the treatment of Lewy body disease.
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
Assumed target
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
INVERSE AGONIST->TARGET |
Experimental drug for the treatment of insomnia.
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
RADIOLIGAND->TARGET | |||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
ANTAGONIST
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
ANTAGONIST->TARGET |
BINDING
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
NON-AGONIST->OFF-TARGET |
Pyr-T produces few to no effects in humans, but some behavioral changes were observed in animal tests.
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
PARTIAL AGONIST->TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
WEAK AGONIST->OFF TARGET |
EC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
PARTIAL AGONIST->TARGET | |||
|
INHIBITOR -> TARGET |
cell:CHO; ligand: 3-H-KETASERIN
BINDING
Ki
|
||
|
PARTIAL AGONIST->TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET |
Kd
|
||
|
INHIBITOR -> TARGET | |||
|
PARTIAL AGONIST->TARGET | |||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
PARTIAL AGONIST->TARGET |
Ki
|
||
|
LIGAND->TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
Retains reasonable potency, with a similar 5-HT2A receptor affinity to MiPT but better selectivity over the 5-HT1A and 5-HT2B subtypes.
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
RADIOLIGAND->TARGET | |||
|
INHIBITOR -> TARGET |
Kd
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT | CHEMICAL |
|